Menu
 

Search abstracts


The evolving drug expenses and healthcare costs of rheumatoid arthritis: a systemic review

  • At: 2018 FIP Congress in Glasgow (Scotland)
  • Type: Poster
  • By: HSIEH, Ping-Hsuan (Institute of Health and Wellbeing, University of Glasgow, Health Economics and Health Technology Assessment)
  • Co-author(s): Ping-Hsuan Hsieh: Health Economics and Health Technology Assessment, Institute of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom;Department of Pharmacy Practice, Tri-Service General Hospital, Taipei, Taiwan, Province of China
    Olivia Wu: Health Economics and Health Technology Assessment, Institute of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom
    Emma McIntosh: Health Economics and Health Technology Assessment, Institute of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom
    Claudia Geue: Health Economics and Health Technology Assessment, Institute of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom
  • Abstract:

    Background

    Over the past couple of decades, there has been major advances in the management of rheumatoid arthritis (RA). It is now recognised that early diagnosis and intensive treatment can limit disease progression and restore physical function in patients with RA. One of the major developments has been the introduction of disease-modifying..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 13 May 2019

FIP Congresses